Cases
GenVec, Inc. (NASDAQ: GNVC)
Merger
Overview
Overview
- Date:
- 4/4/2017
- Company Name - Buyer:
- Intrexon Corporation
- Status:
- Closed/Complete
- Merger Announcement Date:
- 1/24/2017
- Court:
- U.S. Bankruptcy Court: District of Delaware
NEW YORK, April 4, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of Delaware on behalf of all persons or entities who held GenVec, Inc. (NASDAQ: GNVC) securities on March 28, 2017 (the “Class Period”).
On January 24, 2017, the two parties announced the signing of a definitive merger agreement pursuant to which Intrexon Corporation will acquire GenVec in a deal worth $15.9 million. As a result of the merger, Neustar shareholders are only anticipated to receive 0.297 Intrexon shares and one contingent consideration equal to 50% of any milestone or royalty payments received within 36 months after the closing of the transaction for each share of GenVec common stock.
The Complaint alleges that the Company failed to conduct a fair sales process and failed to disclose all material information regarding the sale of the Company.
If you held GenVec securities during the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On January 24, 2017, the two parties announced the signing of a definitive merger agreement pursuant to which Intrexon Corporation will acquire GenVec in a deal worth $15.9 million. As a result of the merger, Neustar shareholders are only anticipated to receive 0.297 Intrexon shares and one contingent consideration equal to 50% of any milestone or royalty payments received within 36 months after the closing of the transaction for each share of GenVec common stock.
The Complaint alleges that the Company failed to conduct a fair sales process and failed to disclose all material information regarding the sale of the Company.
If you held GenVec securities during the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.